363 related articles for article (PubMed ID: 30305115)
1. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Liang X; Briaux A; Becette V; Benoist C; Boulai A; Chemlali W; Schnitzler A; Baulande S; Rivera S; Mouret-Reynier MA; Bouvet LV; De La Motte Rouge T; Lemonnier J; Lerebours F; Callens C
J Hematol Oncol; 2018 Oct; 11(1):124. PubMed ID: 30305115
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
3. Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Boughdad S; Champion L; Becette V; Cherel P; Fourme E; Lemonnier J; Lerebours F; Alberini JL
Cancer Imaging; 2020 Jan; 20(1):11. PubMed ID: 31992361
[TBL] [Abstract][Full Text] [Related]
4. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
6. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
9. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Robertson JFR; Cheung KL; Noguchi S; Shao Z; Degboe A; Lichfield J; Thirlwell J; Fazal M; Ellis MJ
Eur J Cancer; 2018 May; 94():206-215. PubMed ID: 29574365
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Mello-Grand M; Singh V; Ghimenti C; Scatolini M; Regolo L; Grosso E; Zambelli A; Da Prada GA; Villani L; Fregoni V; Baiardi P; Marsoni S; Miller WR; Costa A; Chiorino G
Breast Cancer Res Treat; 2010 Jun; 121(2):399-411. PubMed ID: 20428938
[TBL] [Abstract][Full Text] [Related]
16. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract][Full Text] [Related]
17. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
18. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
[TBL] [Abstract][Full Text] [Related]
20. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]